TW200745085A - Quinoline derivatives - Google Patents

Quinoline derivatives

Info

Publication number
TW200745085A
TW200745085A TW096107089A TW96107089A TW200745085A TW 200745085 A TW200745085 A TW 200745085A TW 096107089 A TW096107089 A TW 096107089A TW 96107089 A TW96107089 A TW 96107089A TW 200745085 A TW200745085 A TW 200745085A
Authority
TW
Taiwan
Prior art keywords
quinoline derivatives
medicament
pharmaceutically
manufacture
processes
Prior art date
Application number
TW096107089A
Other languages
English (en)
Inventor
Frederic Henri Jung
Patrick Ple
Remy Robert Morgentin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200745085A publication Critical patent/TW200745085A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
TW096107089A 2006-03-02 2007-03-02 Quinoline derivatives TW200745085A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06300183 2006-03-02
EP06301103 2006-10-31

Publications (1)

Publication Number Publication Date
TW200745085A true TW200745085A (en) 2007-12-16

Family

ID=38459391

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096107089A TW200745085A (en) 2006-03-02 2007-03-02 Quinoline derivatives

Country Status (6)

Country Link
US (1) US20090076075A1 (zh)
EP (1) EP1994024A2 (zh)
JP (1) JP2009528336A (zh)
AR (1) AR059652A1 (zh)
TW (1) TW200745085A (zh)
WO (1) WO2007099323A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070084172A (ko) * 2004-10-12 2007-08-24 아스트라제네카 아베 퀴나졸린 유도체
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
EP2504342A1 (en) 2009-11-23 2012-10-03 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
JP6499076B2 (ja) 2012-08-30 2019-04-10 アセネックス インコーポレイテッド タンパク質チロシンキナーゼ調節因子としてのｎ−（３−フルオロベンジル）−２−（５−（４−モルホリノフェニル）ピリジン−２−イル）アセトアミド
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN114793434A (zh) 2019-10-18 2022-07-26 加利福尼亚大学董事会 作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW321649B (zh) * 1994-11-12 1997-12-01 Zeneca Ltd
KR19990082330A (ko) * 1996-02-06 1999-11-25 미즈노 마사루 신규 화합물 및 이의 의약 용도
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
WO2000020402A1 (en) * 1998-10-01 2000-04-13 Astrazeneca Ab Chemical compounds
IL142359A0 (en) * 1998-10-08 2002-03-10 Astrazeneca Ab Quinazoline derivatives
KR20080015482A (ko) * 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9922173D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
US6531291B1 (en) * 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
WO2001055116A2 (en) * 2000-01-28 2001-08-02 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
HUP0301236A2 (hu) * 2000-06-28 2003-10-28 Astrazeneca Ab, Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként
WO2002044166A1 (en) * 2000-11-02 2002-06-06 Astrazeneca Ab Substituted quinolines as antitumor agents
JP2004517059A (ja) * 2000-11-02 2004-06-10 アストラゼネカ アクチボラグ 抗腫瘍剤用の４−置換キノリン類
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
SI1463506T1 (sl) * 2001-12-24 2010-01-29 Astrazeneca Ab Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora
CA2473572C (en) * 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
TWI230544B (en) * 2002-07-25 2005-04-01 Veutron Corp Light source control method and apparatus of image scanner
KR20050087863A (ko) * 2002-12-24 2005-08-31 아스트라제네카 아베 퀴나졸린 화합물
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
JP2008515961A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
JP2008515960A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ キノリン誘導体
EP1827434B1 (en) * 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
US7652041B2 (en) * 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity

Also Published As

Publication number Publication date
US20090076075A1 (en) 2009-03-19
WO2007099323A3 (en) 2007-11-15
AR059652A1 (es) 2008-04-16
EP1994024A2 (en) 2008-11-26
JP2009528336A (ja) 2009-08-06
WO2007099323A2 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
TW200745040A (en) Quinoline derivatives
TW200630347A (en) Quinazoline derivatives
MX2010004491A (es) Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares.
IN2012DN03328A (zh)
TW200801003A (en) Novel compounds
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
TW200745114A (en) Novel compounds
MX2009011802A (es) Imidazoquinolinas con propiedades inmunomoduladoras.
TW200639156A (en) New compounds
TW200736232A (en) Pyrimidine derivatives
TW200800999A (en) Novel compounds
TW200833670A (en) Novel compounds 569
TW200621762A (en) Novel compounds
TW200700392A (en) Novel compounds
TW200628466A (en) Quinazoline derivatives
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2013014007A (es) [1,3] oxazinas.
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
TW200738659A (en) Novel compounds
MX2013013692A (es) Halogenoalquil-1,3-oxazinas como inhibidores de beta secretasa 1 (bace1) y/o beta secretasa 2 (bace2).
TW200618801A (en) Pyrimidine derivatives
TW200806300A (en) New therapeutic combinations for the treatment of depression
MX2012003644A (es) Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
MY145647A (en) (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states)
TW200745084A (en) Novel compounds